carvedilol has been researched along with Chronic Lung Injury in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carvedilol treatment also significantly reduced the levels of proinflammatory cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, transforming growth factor (TGF)-β1 and monocyte chemoattractant protein (MCP)-1 in the lung tissue." | 1.43 | Carvedilol attenuates paraquat-induced lung injury by inhibition of proinflammatory cytokines, chemokine MCP-1, NF-κB activation and oxidative stress mediators. ( Amirshahrokhi, K; Khalili, AR, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amirshahrokhi, K | 1 |
| Khalili, AR | 1 |
1 other study available for carvedilol and Chronic Lung Injury
| Article | Year |
|---|---|
Carvedilol attenuates paraquat-induced lung injury by inhibition of proinflammatory cytokines, chemokine MCP-1, NF-κB activation and oxidative stress mediators.
Topics: Animals; Carbazoles; Carvedilol; Chemokine CCL2; Lung Injury; Mice; NF-kappa B; Oxidative Stress; Pa | 2016 |